BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

# Syngene Charts Global Biologics Growth with India at Its Core

June 25, 2025 | Analysis | By Manasee Kurlekar

**At US BIO 2025, Syngene's leadership shared with BioSpectrum CEO Manasee Kurlekar how the company is redefining end-to-end biologics partnerships through innovation, cross-border capacity, and India's largest biologics talent pipeline.**



## Syngene’s Global Biologics Strategy: Flexibility, Innovation, and India’s Growing Talent Pipeline

Syngene’s leadership continues to drive a strategic expansion that underscores its evolution into a global biologics powerhouse. With a sharpened focus on innovation, talent development, and operational flexibility, the company is positioning itself as a trusted partner for multinational biopharma players navigating complex drug development pipelines.

### Expanding Global Reach to Serve Evolving Client Needs

A major element of Syngene’s recent growth has been its deliberate expansion into the US market, including the acquisition of a state-of-the-art facility in Maryland. This addition integrates Syngene into the vibrant biotech ecosystem of Baltimore, while strengthening its ability to provide clients with responsive, proximity-based services in a key global market.

While the US remains the largest center for biologics development, Syngene’s balanced capacity across the US and Asia enables clients to leverage global options while optimizing for speed, cost, and regulatory alignment. The leadership emphasizes that this multi-region flexibility allows customized engagement models, giving clients greater agility as programs advance from research to commercialization.

### Innovation and Integrated Delivery: A Distinct Market Advantage

In an increasingly competitive biologics landscape, Syngene differentiates itself through its fully integrated end-to-end service model — spanning early-stage discovery through to commercial manufacturing. This ability to seamlessly support

clients across the full value chain is further bolstered by recent acquisitions that have expanded both capacity and technological depth.

While Asia has long been recognized for manufacturing cost efficiencies, Syngene aims to go beyond cost advantages by combining scientific excellence with scalable infrastructure and a global mindset. Its capacity to offer integrated biologics solutions from multiple global locations is becoming a defining strength, particularly as biopharma companies seek de-risked, scalable, and flexible outsourcing partnerships.

**Building India’s Largest Biologics Talent Pipeline**

At the heart of Syngene’s global capability is its sustained investment in talent. The company now trains and employs more biologics graduates than any other Indian organization, supported by its own dedicated Biocon University. This initiative ensures a steady pipeline of industry-ready professionals trained on the latest biologics platforms.

Additionally, Syngene has successfully attracted repatriated Indian professionals from leading international institutions, blending global best practices with local scientific expertise. This strategic infusion of talent enables the company to maintain globally competitive standards while scaling up its biologics operations in India and beyond.

**Positioning for the Future**

While managing cross-cultural operations remains part of the complexity of global expansion, Syngene’s leadership emphasizes that its scalable model, integrated innovation platform, and global talent strategy offer a compelling value proposition for biopharma partners worldwide.

As biopharmaceutical innovation accelerates, Syngene is increasingly emerging as a flexible, end-to-end partner capable of supporting complex biologics programs from molecule to market — with a global reach that continues to expand.